One Nucleus Purchasing Scheme: New Deal for Members for Laboratory Products
News Dec 08, 2010
The contract will be implemented on 1 January 2011.
Fisher Scientific has the necessary purchasing power, product range, logistical expertise, value added services and laboratory supplies experience to ensure that One Nucleus delivers cost savings and, at the same time, guarantees unparalleled customer support for its members.
Richard Dickinson, Director of Specialist Services at One Nucleus said “Fisher Scientific has worked hard with their suppliers to get a ‘win-win’ deal for both the Suppliers and One Nucleus Members. I hope the service levels and compelling prices offered by Fisher Scientific will further strengthen our relationship with Fisher Scientific and our members”.
Martin Reilly, Sales Manager for Fisher Scientific said “We are delighted to continue our relationship with One Nucleus. We look forward to serving the needs of the membership in the years to come as we continue to expand the range of products in our portfolio and develop new ways to add value to the services we offer”.
The consortium has an annual spend of over £4 million on laboratory products with over 70 Gold Members The consortium aims to utilise the buying volume of member companies to negotiate and promote Preferred Supply Agreements. The aim is not only to provide bottom line cost savings for members but to also provide added value services that would not normally be available to One Nucleus member companies on an individual basis.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Biopharma Cancer Research Drug Discovery Genomics Research Informatics & Automation Proteomics & Metabolomics
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE